Quince Therapeutics, Inc. Cash
Quince Therapeutics, Inc. (QNCX) had Cash of $1.53 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-08-14
- 2026-06-30: Cash $1.53M.
- 2026-03-31: Cash $3.02M.
- 2025-12-31: Cash $1.41M.
- 2025-09-30: Cash $2.21M.
| Period end | Cash |
|---|---|
| 2026-06-30 | $1.53M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $3.02M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $1.41M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $2.21M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $827.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $2.09M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $2.51M 10-K · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |